PGS allows the specific selection of embryos which are chromosomally normal from amongst all the patient’s embryos in a given cycle of assisted reproduction. This procedure allows us to analyse all 24 chromosome types using array Comparative Genomic Hybridisation (aCGH), in order to discard the possibility of embryonic aneuploidy before implantation.
- Indications to perform PGS Advanced Maternal Age: The risk of finding chromosomal abnormalities increases as the age of the mother increases. Most embryos with an incorrect number of chromosomes fail to implant or miscarry during the first trimester of pregnancy
- Recurrent Miscarriage: Approximately 50% of miscarriages occur due to chromosomal abnormalities. In recurrent miscarriages, 68% of embryos are chromosomally abnormal, and 15% of patients have all chromosomally abnormal embryos.
- Implantation Failure: There is a risk with couples who do not have chromosomal alterations but generate chromosomally abnormal embryos that fail to implant in the uterus.
- Male Factor: Male reproductive function requires a normal sperm function (quantity and quality of sperms).
- Employing PGS for aneuploidy screening in IVF can double ongoing pregnancy rate.
- PGS achieves better reproductive success than FISH.
- ArrayCGH is proven to be scientifically superior to FISH. FISH can only analyse a limited number of chromosomes, whereas aCGH can detect aneuploidies of all the 24 chromosomes.